Metformin in Antiviral Therapy: Evidence and Perspectives

Viruses, Journal Year: 2024, Volume and Issue: 16(12), P. 1938 - 1938

Published: Dec. 18, 2024

Metformin, a widely used antidiabetic medication, has emerged as promising broad-spectrum antiviral agent due to its ability modulate cellular pathways essential for viral replication. By activating AMPK, metformin depletes energy reserves that viruses rely on, effectively limiting the replication of pathogens such influenza, HIV, SARS-CoV-2, HBV, and HCV. Its role in inhibiting mTOR pathway, crucial protein synthesis reactivation, is particularly significant managing infections caused by CMV, EBV. Furthermore, reduces oxidative stress reactive oxygen species (ROS), which are critical replicating arboviruses Zika dengue. The drug also regulates immune responses, differentiation, inflammation, disrupting life cycle HPV potentially other viruses. These diverse mechanisms suppress replication, enhance system functionality, contribute better clinical outcomes. This multifaceted approach highlights metformin’s potential an adjunctive therapy treating wide range infections.

Language: Английский

---

Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis

Published: July 7, 2023

Metabolic-associated fatty liver disease (MAFLD) and its potential impact on the severity of COVID-19 have gained significant attention during pandemic. This review aimed to explore genetic determinants associated with MAFLD, previously recognized as non-alcoholic (NAFLD), their influence outcomes. Various polymorphisms, including PNPLA3 (rs738409), GCKR (rs780094), TM6SF2 (rs58542926), LYPLAL1 (rs12137855), been investigated in relation MAFLD susceptibility progression. Genome-wide association studies meta-analyses revealed associations between these variants risk, well effects lipid metabolism, glucose regulation, function. Furthermore, emerging evidence suggests a possible connection MAFLD-associated polymorphisms COVID-19. Studies exploring indicated outcomes shown conflicting results. Some observed protective effect certain against severe COVID-19, while others reported no associations. highlights importance understanding implications for Further research is needed elucidate precise mechanisms linking develop gene profiling tools early prediction If confirmed severity, could aid identifying high-risk individuals improving management

Language: Английский

---

Genomic Insight into the COVID-19 Severity in MAFLD Patients: A Single-Center Prospective Cohort Study

Published: March 27, 2024

This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes asso-ciated with interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity their association non-alcoholic fatty liver disease (MAFLD). We did not observe a significant between SNPs severity. While IFNAR2 rs2236757 A allele correlated higher creatinine levels upon admission G lower band neu-trophils discharge, these findings require further investigation. The distribution OAS gene (rs10774671, rs10735079 differ MAFLD non-MAFLD patients. Our population's ACE2 rs2074192 genotypes alleles differed from European reference population. Overall, our suggest that specific may be major contributors to patient population, highlighting potential role other genetic factors environmental influences.

Language: Английский

---

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2212 - 2212

Published: Feb. 12, 2024

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related diverse extrapulmonary manifestations this pathology. liver was found be a relatively common organ, beyond the respiratory tract, affected by severe acute syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed essential role chronic (CLD) in general outcome infection. Present concerns field are direct hepatic caused COVID-19 and pre-existing disorders as risk factors for course Which mechanism has key phenomenon—previously existing disorder or failure SARS-CoV-2—is still not fully clarified. Alcoholic (ALD) constitutes another elucidated context Should toxic effects ethanol already developed cirrhosis its perceived causative triggering factor impairment patients? In face these discrepancies, we decided summarize whole picture infection, paying special attention ALD focusing on pathological pathways COVID-19, toxicity cirrhosis.

Language: Английский

---